newsfilter
← Earnings
Earnings Releases·

Unicycive Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss widened to $7.0 million ($0.25/share) from $6.0 million ($0.33/share) in Q3 2025, driven by a $2.2 million R&D decrease offset by a $6.6 million G&A increase due to commercial launch preparation; cash and marketable securities stand at $59 million with a runway extending beyond 2027.
  • FDA accepted the NDA resubmission for oxylanthanum carbonate (OLC) with a PDUFA target action date of March 25, 2027, while the company advances parallel launch preparations and plans to hire an optimized sales force and key commercial leaders in Q1 2027.
  • CMS finalized the 2027 End-Stage Renal Disease Prospective Payment System, establishing a $12.85 per-treatment addition for phosphate binders, which Unicycive views as creating favorable launch conditions subject to FDA approval and TDAPA eligibility confirmation.
  • OLC's NDA includes CMC data from a new manufacturing vendor with a "No Action Indicated" status, while the lead investigational treatment UNI-494 received orphan drug designation for preventing Delayed Graft Function and completed a Phase 1 safety study.
Company
UNICYCIVE THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology